相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells
Lilly Magdalena Weiss et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
F. de Braud et al.
ANNALS OF ONCOLOGY (2015)
BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments
Rodrigo F. E. Bogado et al.
ANTI-CANCER DRUGS (2015)
Activation of the endomitotic spindle assembly checkpoint and thrombocytopenia in Plk1-deficient mice
Marianna Trakala et al.
BLOOD (2015)
A phase I study of volasertib combined with afatinib, in advanced solid tumors
Jean-Pascal Machiels et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia
Yukio Kobayashi et al.
CANCER SCIENCE (2015)
Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs
M. Hugle et al.
CELL DEATH AND DIFFERENTIATION (2015)
A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer
Peter M. Ellis et al.
CLINICAL LUNG CANCER (2015)
Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
Ahmad Awada et al.
INVESTIGATIONAL NEW DRUGS (2015)
Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines
Claudia Muench et al.
LEUKEMIA RESEARCH (2015)
Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1
Chung-Pu Wu et al.
MOLECULAR PHARMACEUTICS (2015)
Understanding the Polo Kinase machine
V. Archambault et al.
ONCOGENE (2015)
Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment
Xiaoqi Liu
TRANSLATIONAL ONCOLOGY (2015)
Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer
Neil E. Bhola et al.
CANCER RESEARCH (2015)
Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery
Klaus Strebhardt et al.
EXPERT OPINION ON DRUG DISCOVERY (2015)
Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1
Monika Raab et al.
MOLECULAR ONCOLOGY (2015)
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
B. T. Gjertsen et al.
LEUKEMIA (2015)
A novel role for Plk4 in regulating cell spreading and motility
C. O. Rosario et al.
ONCOGENE (2015)
Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia
Dorothea Rudolph et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Targeting polo-like kinase 1 in acute myeloid leukemia
Joseph M. Brandwein
THERAPEUTIC ADVANCES IN HEMATOLOGY (2015)
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Hartmut Doehner et al.
BLOOD (2014)
Polo-like kinase-1 in DNA damage response
Sun-Yi Hyun et al.
BMB REPORTS (2014)
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
C-C Lin et al.
BRITISH JOURNAL OF CANCER (2014)
An Open-Label, Single-Arm, Phase 2 Trial of the PoloLike Kinase Inhibitor Volasertib ( BI 6727) in Patients With Locally Advanced or Metastatic Urothelial Cancer
Walter M. Stadler et al.
CANCER (2014)
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia
Antonino Maria Sparta et al.
CELL CYCLE (2014)
Large-Scale Label-Free Comparative Proteomics Analysis of Polo-Like Kinase 1 Inhibition via the Small-Molecule Inhibitor BI 6727 (Volasertib) in BRAFV600E Mutant Melanoma Cells
Brian D. Cholewa et al.
JOURNAL OF PROTEOME RESEARCH (2014)
Polo-like kinases: structural variations lead to multiple functions
Sihem Zitouni et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Initial Testing (Stage 1) of the Polo-Like Kinase Inhibitor Volasertib (BI 6727), by the Pediatric Preclinical Testing Program
Richard Gorlick et al.
PEDIATRIC BLOOD & CANCER (2014)
In vitro targeting of Polo-like kinase 1 in bladder carcinoma: Comparative effects of four potent inhibitors
Maria Sol Brassesco et al.
CANCER BIOLOGY & THERAPY (2013)
Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma
J. A. Pezuk et al.
CANCER GENE THERAPY (2013)
The Role of Polo-like Kinase 1 in Carcinogenesis: Cause or Consequence?
Brian D. Cholewa et al.
CANCER RESEARCH (2013)
Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53
Mourad Sanhaji et al.
CELL CYCLE (2013)
Plk1: unexpected roles in DNA replication
Ranadip Mandal et al.
CELL RESEARCH (2013)
Targeting prostate cancer cell lines with polo-like kinase 1 innibitors as a single agent and in combination with histone deacetylase inhibitors
Michel D. Wissing et al.
FASEB JOURNAL (2013)
Polo-Like Kinase 2 Is a Mediator of Hedgehog Survival Signaling in Cholangiocarcinoma
Christian D. Fingas et al.
HEPATOLOGY (2013)
A High-Content Small Molecule Screen Identifies Sensitivity of Glioblastoma Stem Cells to Inhibition of Polo-Like Kinase 1
Davide Danovi et al.
PLOS ONE (2013)
Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation
Mechthild Krause et al.
RADIOTHERAPY AND ONCOLOGY (2013)
Outlier Kinase Expression by RNA Sequencing as Targets for Precision Therapy
Vishal Kothari et al.
CANCER DISCOVERY (2013)
Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy
Frank Louwen et al.
ONCOTARGET (2013)
p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors
Mourad Sanhaji et al.
CELL CYCLE (2012)
Phase I study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours
A. Frost et al.
CURRENT ONCOLOGY (2012)
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2012)
Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer
Zhao-Xia Wang et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2012)
TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens
Yuichi Hikichi et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The Structure of the Plk4 Cryptic Polo Box Reveals Two Tandem Polo Boxes Required for Centriole Duplication
Lauren K. Slevin et al.
STRUCTURE (2012)
Polo-like kinase 1 as target for cancer therapy
Lily Weiss et al.
EXPERIMENTAL HEMATOLGY & ONCOLOGY (2012)
Preclinical synergy of Plk1 inhibitors and HDACIs
Channing J. Paller et al.
CANCER RESEARCH (2011)
Preclinical characterization of TKM-080301, a lipid nanoparticle formulation of a small interfering RNA directed against polo-like kinase
Sean C. Semple et al.
CANCER RESEARCH (2011)
From Plk1 to Plk5 Functional evolution of Polo-like kinases
Guillermo de Carcer et al.
CELL CYCLE (2011)
PLK1 as an oncology target: current status and future potential
Campbell McInnes et al.
DRUG DISCOVERY TODAY (2011)
Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions
El Mustapha Bahassi
EXPERIMENTAL BIOLOGY AND MEDICINE (2011)
Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies
Daniel C. Christoph et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Plk5, a Polo Box Domain-Only Protein with Specific Roles in Neuron Differentiation and Glioblastoma Suppression
Guillermo de Carcer et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells
Shilpa Tyagi et al.
BIOCHEMICAL PHARMACOLOGY (2010)
An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors
Ralf-Dieter Hofheinz et al.
CLINICAL CANCER RESEARCH (2010)
Future Prospect of RNA Interference for Cancer Therapies
Eishi Ashihara et al.
CURRENT DRUG TARGETS (2010)
Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors
Italo Beria et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Klaus Strebhardt
NATURE REVIEWS DRUG DISCOVERY (2010)
Plk4 is required for cytokinesis and maintenance of chromosomal stability
Carla O. Rosario et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Distinct Concentration-Dependent Effects of the Polo-like Kinase 1-Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis
Aidan G. Gilmartin et al.
CANCER RESEARCH (2009)
A Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis
Wolfgang Reindl et al.
CHEMBIOCHEM (2009)
Identification and Validation of a Potent Type II Inhibitor of Inactive Polo-like Kinase 1
Sarah Keppner et al.
CHEMMEDCHEM (2009)
BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
Dorothea Rudolph et al.
CLINICAL CANCER RESEARCH (2009)
Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma
Yan-Bin Feng et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Deficiency in Chromosome Congression by the Inhibition of Plk1 Polo Box Domain-dependent Recognition
Nobumoto Watanabe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
The small organic compound HMN-176 delays satisfaction of the spindle assembly checkpoint by inhibiting centrosome-dependent microtubule nucleation
Michael A. DiMaio et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Polo-like kinases: conservation and divergence in their functions and regulation
Vincent Archambault et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1
Sang-Moon Yun et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2009)
Inhibition of polo-like kinase 1 by blocking Polo-box domain-dependent protein-protein interactions
Wolfgang Reindl et al.
CHEMISTRY & BIOLOGY (2008)
Polo on the rise -: from mitotic entry to cytokinesis with Plk1
Mark Petronczki et al.
DEVELOPMENTAL CELL (2008)
RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells
C. Yu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
Polo-Like Kinase 1 Is Essential for Early Embryonic Development and Tumor Suppression
Lin-Yu Lu et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Polo-like kinase 1 is involved in invasion through extracellular matrix
Aylin Rizki et al.
CANCER RESEARCH (2007)
Use of the novel Plk1 inhibitor ZK-Thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis
Anna Santamaria et al.
MOLECULAR BIOLOGY OF THE CELL (2007)
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo
Martin Steegmaier et al.
CURRENT BIOLOGY (2007)
In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1
Timothy J. Lansing et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Targeted anti-mitotic therapies: can we improve on tubulin agents?
Jeffrey R. Jackson et al.
NATURE REVIEWS CANCER (2007)
Probing cell-division phenotype space and Polo-like kinase function using small molecules
Ulf Peters et al.
NATURE CHEMICAL BIOLOGY (2006)
Opinion - Targeting polo-like kinase 1 for cancer therapy
K Strebhardt et al.
NATURE REVIEWS CANCER (2006)
The Polo kinase Plk4 functions in centriole duplication
R Habedanck et al.
NATURE CELL BIOLOGY (2005)
Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues
JA Winkles et al.
ONCOGENE (2005)
Polo-like kinases and oncogenesis
F Eckerdt et al.
ONCOGENE (2005)
Polo-like kinases in the nervous system
DP Seeburg et al.
ONCOGENE (2005)
Progress in the discovery of polo-like kinase inhibitors
C McInnes et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2005)
Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma
W Weichert et al.
BRITISH JOURNAL OF CANCER (2004)
Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers:: Identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas
S Yamada et al.
ONCOGENE (2004)
Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation
K Ando et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (Taxol)-exposed cells
TF Burns et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers
T Takahashi et al.
CANCER SCIENCE (2003)
A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of plk1 in u-2 OS cells
YS Seong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease
L Kneisel et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2002)
Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells
B Spänkuch-Schmitt et al.
ONCOGENE (2002)
Prognostic value of pololike kinase expression in melanomas
K Strebhardt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
